Biogen Inc

NASDAQ: BIIB
$157.69
-$1.02 (-0.6%)
Closing Price on November 26, 2024

BIIB Articles

Shares of Alexion Pharmaceuticals saw a handy gain early on Wednesday after the company announced that there would be changes in its leadership.
The May 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
The May 15 short interest data have been compared with the previous report, and moves in the selected biotech stocks were mixed.
The April 28 short interest data have been compared with the previous report, and moves in the selected biotech stocks were mixed.
With the markets once again bumping up against and trading around all-time highs, we were somewhat surprised to see as much insider buying as we did last week.
The April 13 short interest data have been compared with the previous report, and moves in the selected biotech stocks were mixed.
The March 31 short interest data have been compared with the previous report, and short interest decreased in most of the selected biotech stocks.
The health care sector in general has rallied since Trump took over the presidency, but now that his repeal of the ACA fell through, the health care rally is called into question.
March 16, 2017: The S&P 500 closed lower on the day, down 0.17% and 4.01 points to 2,381.26. Separately the DJIA closed down 0.09% on the day at 20,932.16, down approximately 17.94 points. The...
The top analyst upgrades, downgrades and initiations seen on Thursday include Biogen, Goldcorp, GoPro, Oracle, Sirius XM, Tyson Foods and Ciena.
The February 28 short interest data have been compared with the previous report, and short interest decreased in most of the selected biotech stocks.
The top analyst upgrades, downgrades and initiations seen on Thursday include American Express, Amgen, Encana, Gilead Science and Tesla.
Thursday’s top analyst upgrades, downgrades and initiations include Activision Blizzard, Anheuser-Busch, Amphenol, Biogen, Goldman Sachs BDC and Pure Storage.
The February 15 short interest data have been compared with the previous report, and short interest increased in all the selected biotech stocks.
One area is dirt cheap now, and in some cases pays dividends and has big growth prospects, and that is the large cap biotechs.